Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis

Clinical Journal of the American Society of Nephrology, 05/08/2012

Clinical and histopathologic data suggest a response to eculizumab in some but not all subjects with dense deposit disease and C3 glomerulonephritis. Elevation of serum membrane attack complex before treatment may predict response. Additional research is needed to define the subgroup of dense deposit disease/C3 glomerulonephritis patients in whom eculizumab therapy can be considered.

Print Article Summary Cat 2 CME Report